{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morschhauser F"],"funding":["NCI NIH HHS"],"pagination":["2199-2207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11333271"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(8)"],"pubmed_abstract":["An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product. The phase 2 TRANSCEND FL study evaluated liso-cel in patients"],"journal":["Nature medicine"],"pubmed_title":["Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study."],"pmcid":["PMC11333271"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Papuga J","Reguera Ortega JL","Skarbnik A","Kamdar M","Farazi T","Izutsu K","Ardeshna K","Goto H","Barbui AM","Karmali R","Avilion A","Cartron G","Mielke S","de Vos S","Abramson JS","Dahiya S","Kahl B","Borchmann P","Morschhauser F","Palomba ML","Martin Garcia-Sancho A","Fasan O","Vedal M","Kuruvilla J","Dreyling M","Ghesquieres H","Nishii R","Viardot A","Fleury I","Lymp J","Kumar J","Jager U","Nastoupil LJ"],"additional_accession":[]},"is_claimable":false,"name":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.","description":"An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product. The phase 2 TRANSCEND FL study evaluated liso-cel in patients","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-03T00:41:41.889Z","creation":"2025-05-18T13:29:55.13Z"},"accession":"S-EPMC11333271","cross_references":{"pubmed":["38830991"],"doi":["10.1038/s41591-024-02986-9"]}}